#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Testing for COVID-19: a few points to remember


Authors: Zuzana Krátká 1,3;  Štěpánka Luxová 1;  Karin Malíčková 2;  Tomáš Fürst 3,4;  Halina Šimková 3,5
Authors‘ workplace: Imunologická laboratoř GENNET, s. r. o. 1;  Klinické centrum ISCARE, a. s. 2;  Katedra matematické analýzy a aplikací matematiky PřF UP Olomouc 4;  Znalecký a expertizní ústav, z. ú., Praha 5;  BIN – Centrum pro bayesovskou inferenci 34
Published in: Čas. Lék. čes. 2020; 159: 72-77
Category: Original Article

Overview

Diagnostic approaches to COVID-19 include clinical history, PCR tests for the presence of SARS-CoV-2 virus and detection of antibodies. By combining these three approaches, the seroprevalence of anti–SARS-CoV-2 antibodies can be examined in healthcare teams.

The aim of the study was to examine the seroprevalence of anti–SARS-CoV-2 antibodies in a population of healthcare professionals 6 - 8 weeks after the first COVID-19 case was detected in the Czech Republic.

A total of 269 subjects were enrolled in the study (187 women, 82 men) with a median age of 45.9 years (21 – 71 years). We used a questionnaire to ascertain travel history and clinical signs of any respiratory tract infection. Blood samples were collected, and IgG levels were analysed in all samples. The level of IgA antibodies was analysed in those positive for IgG. PCR testing was performed in cases testing positive for presence of antibodies. The enzyme-linked immunosorbent assay (ELISA) test system for SARS-CoV-2 from Euroimmun (Germany) was used to analyse immunoglobulin levels.

17 % of the tested cohort reported symptoms compatible with COVID-19 and 35.8 % reported history of international travel. There were 5 subjects positive IgG cases (of 269; 1.85 %), and one IgA positive and IgG borderline positive subject (0.37 %). There was only one PCR positive subject. Anti SARS-CoV-2 antibodies were thus detected in 2.22% of participating health professionals.

This article shows the pitfalls of the testing methods and highlights the necessity of using a correct testing algorithm, considering the character of the tested population and the expected low prevalence.

Keywords:

ELISA – sensitivity – specificity – SARS-CoV-2 – COVID-19 – antibody – positive predictive value – IgA – IgG – rapid test


Sources
  1. Pueyo T. Coronavirus: learning how to dance. Part 1: A dancing masterclass, or what we can learn from countries around the world. Medium, 2020 Apr 20. Dostupné na: https://medium.com/@tomaspueyo/coronavirus-learning-how-to-dance-b8420170203e
  2. Hasell J, Ortiz-Ospina E, Mathieu E et al. Coronavirus (COVID-19) testing. Statistics and Research. Our World in Data, 2020. Dostupné na: https://ourworldindata.org/covid-testing
  3. ÚZIS ČR. Studie SARS-CoV-2-CZ-Preval. Ústav zdravotnických informací a statistiky ČR, 6. 5. 2020. Dostupné na: https://covid-imunita.uzis.cz/res/file/prezentace/20200506-dusek.pdf
  4. WHO. Laboratory testing strategy recommendations for COVID-19. Interim guidance. World Health Organization, 2020 Mar 21. Dostupné na: https://apps.who.int/iris/bitstream/handle/10665/331509/WHO-COVID-19-lab_testing-2020.1-eng.pdf
  5. Xu G, Yang Y, Du Y et al. Clinical pathway for early diagnosis of COVID-19: Updates from experience to evidence-based practice. Clin Rev Allergy Immunol 2020 Apr 24; 1–12, doi: 10.1007/s12016-020-08792-8.
  6. Bloch EM, Shoham S, Casadevall A et al. Deployment of convalescent plasma for the prevention and treatment of COVID-19. J Clin Invest 2020 Apr 7; 138745, doi: 10.1172/JCI138745.
  7. Theel ES, Slev P, Wheeler S et al. The role of antibody testing for SARS-CoV-2: Is there one? J Clin Microbiol 2020 Apr 29; JCM.00797-20, doi: 10.1128/JCM.00797-20.
  8. Fürst T, Strójil J, Šimková H. Velká drogová kocovina. FinMag, 25. 6. 2019. Dostupné na: https://finmag.penize.cz/kaleidoskop/407932-velka-drogova-kocovina
  9. Okba NMA, Müller MA, Li W et al. Severe acute respiratory syndrome coronavirus 2-specific antibody responses in coronavirus disease 2019 patients. Emerg Infect Dis 2020 Apr 8; 26(7), doi: 10.3201/eid2607.200841.
  10. FIND. SARS-CoV-2 diagnostic pipeline. Foundation for Innovative New Diagnostics, 2020. Dostupné na: www.finddx.org/covid-19/pipeline/?section=immunoassays#diag_tab
  11. Goodman SL. Coronavirus in the crosshairs, Part 7: Diagnostic tests. The Antibody Society, 2020 Apr 28. Dostupné na: www.antibodysociety.org/uncategorized/coronavirus-in-the-crosshairs-part-7-diagnostic-tests
  12. FIND. FIND evaluation update: SARS-CoV-2 immunoassays. Foundation for Innovative New Diagnostics, 2020. Dostupné na: www.finddx.org/covid-19/sarscov2-eval-immuno
  13. Li X, Geng M, Peng Y el al. Molecular immune pathogenesis and diagnosis of COVID-19. J Pharm Anal 2020 Mar 5, doi: 10.1016/j.jpha.2020.03.001.
  14. Monto AS, DeJonge PM, Callear AP et al. Coronavirus occurrence and transmission over 8 years in the hive cohort of households in Michigan. J Infect Dis 2020 Apr 4; jiaa161, doi: 10.1093/infdis/jiaa161
Labels
Addictology Allergology and clinical immunology Angiology Audiology Clinical biochemistry Dermatology & STDs Paediatric gastroenterology Paediatric surgery Paediatric cardiology Paediatric neurology Paediatric ENT Paediatric psychiatry Paediatric rheumatology Diabetology Pharmacy Vascular surgery Pain management Dental Hygienist
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#